Endocrine pancreatic tumors: Factors correlated with survival

Annals of Oncology

Volumn 16, Issue 11, 2005, Pages 1806-1810

  Tomassetti, Paola ^a   Campana, D ^a   Piscitelli, L ^a   Casadei, R ^a   Santini, D ^a   Nori, F ^a   Morselli Labate, A M ^a   Pezzilli, R ^a   Corinaldesi, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Endocrine pancreatic tumor; Gastrinoma; Multiple endocrine neoplasia; Octreotide; Surgical procedure

Indexed keywords

SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOSCOPIC ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL CARCINOMA; PANCREAS SURGERY; PANCREATOGRAPHY; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME;

EID: 27744575208     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi358     Document Type: Article

References (32)

1. Eriksson B, Oberg K. Neuroendocrine tumours of the pancreas. Br J Surg 2000; 87: 129-131.
2. Moldow RE, Connelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology 1968; 55: 677-686.
3. Lam KY, Lo CY. Pancreatic endocrine tumour: A 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997; 23: 36-42.
4. De Vita V, Hellman S, Rosemberg S. Cancer Principles and Practice of Oncology. Philadelphia: JB Lippincott 1985.
5. Kloppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988; 183: 155-168.
6. Maton PN, Gardner JD, Jensen RT. Diagnosis and management of Zollinger-Ellison syndrome. Endocrinol Metab Clin North Am 1989; 18: 519-543.
7. Phan GQ, Yeo CJ, Hruban RH et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 1998; 2: 472-482.
8. de Herder WW, Krenning EP, van Eijck CH, Lamberts SW. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocr Relat Cancer 2004; 11: 19-34.
9. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004; 11: 1-18.
10. Gullo L, Migliori M, Falconi M et al. Nonfunctioning pancreatic endocrine tumors: A multicenter clinical study. Am J Gastroenterol 2003; 98: 2435-2439.
11. Broder LE, Carter SK. Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med 1973; 79: 101-107.
12. Kloppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Pract 1988; 183: 155-168.
13. Chu QD, Hill HC, Douglass HO Jr et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002: 9: 855-862.
14. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumors. Heidelberg: Springer-Verlag: 2000.
15. Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet cell tumors. Surgery 1986; 99: 671-678.
16. Venkatesh S, Ordonez NG, Ajani J et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 1990; 65: 354-357.
17. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120: 139-161.
18. Eriksson B, Skogseid B, Lundqvist G et al. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990; 65: 1883-1890.
19. Corleto VD, Annibale B, Gibril F et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001; 15: 1555-1561.
20. Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol 2005; 89: 143-150.
21. Evans DB, Skibber JM, Lee JE et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993; 114: 1175-1181.
22. Grama D, Eriksson B, Martensson H et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992; 16: 632-639.
23. Thompson GB, van Heerden JA, Grant CS et al. Islet cell carcinomas of the pancreas: A twenty-year experience. Surgery 1988; 104: 1011-1017.
24. Madeira I, Terris B, Voss M et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998; 43: 422-427.
25. Wiedenmann B. Neuroendocrine tumors of the pancreas. Natural history and therapeutic options. Gastroenterol Clin Biol 2003; 27 (3 Suppl): S26-S30.
26. La RS, Sessa F, Capella C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429: 323-333.
27. Rindi G, Candusso ME, Solcia E. Molecular aspects of the endocrine tumours of the pancreas and the gastrointestinal tract. Ital J Gastroenterol Hepatol 1999; 31 (Suppl 2): S135-S138.
28. Weber HC, Venzon DJ, Lin JT et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 1995; 108: 1637-1649.
29. Lowney JK, Frisella MM, Lairmore TC, Doherty GM. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: Correlation with primary tumor size. Surgery 1998; 124: 1043-1048.
30. Alexakis N, Connor S, Ghaneh P et al. Hereditary pancreatic endocrine tumours. Pancreatology 2004; 4: 417-433.
31. Rigaud G, Missiaglia E, Moore PS et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: Identification of two molecular subgroups with clinical implications. Cancer Res 2001; 61: 285-292.
32. Norton JA, Warren RS, Kelly MG et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134: 1057-1063.